For adults with moderate to severe Crohn’s disease in whom TNF blockers did not work well

Proven results

with RINVOQ

RINVOQ results that won’t back down

Many people(~4 out of 10) taking RINVOQ achieved

meaning few or no symptoms (at 12 weeks and 1 year)

Click on the tabs below to see proven RINVOQ results

In Study 1, 2.6 times more people, 37% taking RINVOQ 45mg (n=273) experienced rapid symptom relief vs 14% on placebo (n=146).
In Study 1, 3 times more people, 33% taking RINVOQ 45mg (n=324) experienced rapid symptom relief vs 12% on placebo (n=171). In Study 2, 1.5 times more people, 37% taking RINVOQ 45mg (n=295) experienced rapid symptom relief vs 24% on placebo (n=143).
In Study 1, 2.7 times more people, 30% taking RINVOQ 45mg (n=96) achieved steroid-free remission vs 11% on placebo (n=53).
In Study 1, 2.7 times more people, 30% taking RINVOQ 45mg (n=96) achieved steroid-free remission vs 11% on placebo (n=53). In Study 2, 3 times more people, 40% taking RINVOQ 45mg (n=108) achieved steroid-free remission vs 13% on placebo (n=54).
In Study 1, 11 times more people, 34% taking RINVOQ 45mg (n=273) experienced visibly reduced damage of the intestinal lining caused by excess inflammation* vs 3% on placebo (n=146).

*Based on areas that were assessed with endoscopy.

In Study 1, 11 times more people, 34% taking RINVOQ 45mg (n=273) experienced visibly reduced damage of the intestinal lining caused by excess inflammation* vs 3% on placebo (n=146). In Study 2, 3.5 times more people, 46% taking RINVOQ 45mg (n=295) experienced visibly reduced damage of the intestinal lining caused by excess inflammation* vs 13% on placebo (n=143).

*Based on areas that were assessed with endoscopy.

In Study 3, 3 times more people, 42% taking RINVOQ 15mg (n=113) & 53% taking RINVOQ 30mg (n=119) achieved steroid-free remission vs 14% on placebo (n=111).
In Study 3, 4 times more people, 28% taking RINVOQ 15mg (n=113) & 41% taking RINVOQ 30mg (n=119) experienced visibly reduced damage of the intestinal lining caused by excess inflammation* vs 7% on placebo (n=111).

*Based on areas that were assessed with endoscopy.

Keep scrolling to see trial data and real patient endoscopy images at 12 weeks and 1 year

PATIENT 1

Real Clinical Trial patient endoscopy images. Adult patient with moderate to severe Crohn’s disease received RINVOQ 45 mg (induction) and 15 mg (maintenance), once daily. Patient had previously used a medicine called a tumor necrosis factor (TNF) blocker that either did not work well or could not be tolerated.

Patient 1’s colon before taking RINVOQ

 

 

Before RINVOQ

Patient 1’s colon at week 12 on RINVOQ

Week 12

Patient 1’s colon after 1 year on RINVOQ

1 Year

Patient achieved endoscopic remission at Week 12 and also at 1 year. At 12 weeks, 19% of people taking RINVOQ 45 mg (N=273) achieved endoscopic remission (little to no visible evidence of active Crohn’s) vs 3% of patients taking placebo (N=146) in Study 1. At 1 year, 19% of people taking RINVOQ 15 mg (N=113) achieved endoscopic remission (little to no visible evidence of active Crohn’s) vs 5% of patients taking placebo (N=111) in Study 3.

Individual results may vary.

PATIENT 2

Real Clinical Trial patient endoscopy images. Adult patient with moderate to severe Crohn’s disease received RINVOQ 45 mg (induction) and 30 mg (maintenance), once daily. Patient had previously used a medicine called a tumor necrosis factor (TNF) blocker that either did not work well or could not be tolerated.

Patient 2’s rectum before taking RINVOQ

Before RINVOQ

Patient 2’s rectum at week 12 on RINVOQ

Week 12

Patient 2’s rectum after 1 year on RINVOQ

1 Year

Patient achieved endoscopic response at Week 12 and also at 1 year.

Individual results may vary.

Your doctor will decide which maintenance dose (15 mg or 30 mg) is right for you.

In clinical studies,

RINVOQ helped people achieve visibly reduced damage of the intestinal lining caused by excess inflammation.* (Endoscopic response)

At 12 weeks, 34% of people taking RINVOQ 45 mg (N=273) achieved visibly reduced damage of the intestinal lining* vs 3% of patients taking placebo (N=146) in Study 1, and 46% of people taking RINVOQ 45 mg (N=295) vs 13% of patients taking placebo (N=143) in Study 2.

At 1 year, 28% of people taking RINVOQ 15 mg (N=113) and 41% of people taking RINVOQ 30 mg (N=119) achieved visibly reduced damage of the intestinal lining* vs 7% of patients taking placebo (N=111) in Study 3.

*Based on endoscopy at 12 weeks and 1 year.

Quick poll

Still experiencing Crohn’s disease symptoms after a TNF blocker like HUMIRA® or REMICADE®?

RINVOQ is a once-daily pill that treats patients with moderate to severe Crohn’s disease in whom TNF blockers did not work well. It is important to continue to partner with your gastroenterologist.

What is RINVOQ? >

RINVOQ is a once-daily pill that treats patients with moderate to severe Crohn’s disease in whom TNF blockers did not work well. It is important to continue to partner with your gastroenterologist.

What is RINVOQ? >

REMICADE® (infliximab) is a registered trademark of Janssen Biotech, Inc.

Looking to
Partner with a gastro?

Find a doctor to help you develop a treatment plan.

Make RINVOQ part of your routine

Get the facts about taking RINVOQ for Crohn’s

Is your current treatment meeting your goals?

Use our discussion tool to help start a conversation with your doctor.

Looking for a specialist to help treat your Crohn’s disease?

Find a gastroenterologist near you.